Atrys Health: Cash Flow Is Finally Arriving as the Debt Bill Shrinks

For years, Atrys Health told the market a growth story it paid for with debt. The Spanish precision-medicine company — it runs cancer diagnostics, pathology and radiotherapy across Spain, Portugal and Latin America — grew by buying businesses, and by 2021 it piled on leverage to snap up its own workplace-safety arm, ASPY. Investors who lived through that keep pricing Atrys as a debt-heavy serial acquirer that cannot earn its keep. The company still lost €6.4 million in the first half of 2026. Nothing about that headline is wrong.

But a different number, delivered in the same report, is the one that makes the old story stale: Atrys cut its net financial debt 79.2% to €35.4 million. That is a balance-sheet reset, not a target six months out. And in the next 12 months the bill it used to pay is what shows up in the cash flow. This is the patient, financially-undeniable version of an expectations reset — the market is still pricing the old risk profile while the operating setup is already getting cleaner.

The debt bill was the whole problem

The mechanism is worth spelling out, because it is the bridge the earnings report quietly walked over. In the first half of 2026 Atrys's financial expenses fell 43.3% year over year, and management attributed €4.4 million of savings to paying down debt. Against a half-year net loss of €6.4 million, that €4.4 million of interest no longer paid is not a rounding error — it closes roughly two-thirds of the remaining gap to breakeven on its own, before a single extra euro of revenue.

The source of the money was a sale management completed in January: it divested the ASPY prevention division for €145 million, taking a loss relative to what it paid four years earlier rather than clinging to a business that no longer fit. The trade-off is exactly what a clean balance sheet buys. Alongside the debt reduction, the company guided that the deal should also cut around €13 million of annual financial expenses. Done with no financial engineering — a straightforward asset sale, proceeds to the lenders.

Cash flow is the proof, and it just turned

That interest saving is the quiet piece. The loud piece is what operating cash flow is starting to do. In the first half of 2026 it jumped 191.5% to €7.2 million, helped by both the EBITDA gains and lower capital spending. Before you decide this is a beaten-down-story recap, notice that the trajectory is positive, not merely intact.

Revenue rose 9.4% to €77.7 million in the half, and growth accelerated as the period went on — from 6.3% in the first quarter to 12.3% in the second. EBITDA climbed 21.3% to €9.3 million with the margin at 11.9%. The growth engine is where management has pointed all along: oncology, which is driving an aggressive buildout in Mexico — up 151.1% in the half — and Latin America overall, which grew 26.1%.

Management's own 2026 targets, reiterated with the results, put numbers to the proof path: revenue of €156.5 million (+11%), EBITDA of €20.5 million (+40%) and operating cash flow of €13.5 million, up 125% from the prior year. On roughly €190 million of equity and the now-modest €35.4 million of debt, that forward operating cash flow is a low-teens multiple and enterprise value sits around 11 times guided EBITDA. The market has not paid up for cash that is only just arriving — which is precisely the moment a reset entry looks for.

What has to hold, and what would break it

Atrys is still unprofitable at the net line, and the honest caveat is that a large part of that is depreciation and amortization carried over from years of acquisitions. That is why the proof point is cash flow, not net income, and why the report deserves the standard scrutiny rather than cheerleading. Two live tests matter.

First, operating cash flow. The first half produced €7.2 million of the €13.5 million full-year target — a little over half, meaning the second half has to deliver the rest. If it does, the earnings bridge gets far more credible. Second, restraint. The whole case rests on a company that stopped buying its way to growth; if management relapses into debt-funded deals, the reset stalls. Watch, too, for the obvious geographic risk of a Mexican buildout racing to profitability.

The setup is clean: a company that took a real loss on a subscale division to remove the biggest drag on its economics, whose cash flow has already inflected — and whose biggest drag is now the interest bill it no longer pays. I can be wrong again — a cash-flow miss in the second half would test the whole thesis. But this is not about excitement. It is about a business that may soon look a lot harder to dismiss once the free cash flow shows up. The market has been pricing the old Atrys; the numbers say a new one is already in the books.